ClinicalTrials.gg
TerminatedNCT02316847Updated Jul 30, 2018Results posted

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

A Phase 2 interventional study of diazepam nasal spray in Epilepsy, sponsored by Acorda Therapeutics. Terminated at 33 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-07-30.

Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Non-randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing diazepam in Epilepsy — none open to participants now, none under way, none of them phase 3. Diazepam · Epilepsy.

Enrollment
4th of 10
126 · median 68
Started
2014
the only one that year
Phase 2
3 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
3 of 10
Acorda Therapeutics

Among the 10 studies testing diazepam in Epilepsy, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 2, and was the 5th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 10 studies testing diazepam in Epilepsy is open now. The open studies under Epilepsy, anywhere →

Where they have run

About diazepam

Diazepam: first FDA approval 1963 (VALIUM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing diazepam in Epilepsy as a file.
02

Study summary

This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).

03

Conditions studied

  • Epilepsy

Keywords

  • Cluster Seizures
  • Seizures
  • Clusters
  • Acute repetitive seizures
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of drug-resistant epilepsy
  • Patients who experience multiple episodes of acute repetitive seizures requiring at least one concomitant antiepileptic drug (AED)
  • Occurrence of at least 3 seizure clusters within the past 12 months, including at least one cluster in the 4 months prior to the Screening Visit
  • A caregiver must consent to participate together with the subject for purposes of observation and data collection
  • The caregiver must be present when the product is administered
  • Screening body weight between 26 to 111 kg, inclusive

Exclusion criteria

Exclusion Criteria:

  • Female subject who is pregnant, breastfeeding, or planning to become pregnant
  • Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam
  • Known allergy or to diazepam, related drugs, or any of the formulation components
  • Positive screening test for ethanol or other drugs of abuse
  • Unable to receive medications intranasally
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    diazepam nasal spray (Adults)

    One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.

    Drug: diazepam nasal spray

  • Experimental
    Diazepam Nasal Spray (Adolescents)

    One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.

    Drug: diazepam nasal spray

Interventions

06

What researchers measure

Primary outcomes

  1. Olfactory Changes as Measured by the Smell Identification Test (SIT)

    The SIT is a 50-item multiple-choice standardized test of olfactory function. Scoring of the test in the ability to smell ranges from normal (Normosmia: score 35 - 40 Women; 34 - 40 Men); to inability to smell (Anosmia score 6 - 18); or Malingering (not engaged in the test) ranges 0 - 5.

    Time frame: Screening, weeks 12, 24, 36, 48 and 51

  2. Change From Baseline (Screening) in Nasal Mucosa.

    Change from baseline treatment visits using a focused nasal exam was based on a scale of nasal irritation "none" to Grade 4 "septal perforation."

    Time frame: Screening, Weeks 12, 24, 36, 48 and 51

  3. Change in Taste as Measured by a Taste Change Questionnaire

    Change in taste questionnaire was administered to subjects at every study visit only if the subject complained of a change in taste or as needed to report a related AE. The taste change profile included sweet, salty, sour, bitter, oily, sharp, chalky, metallic. The subject rated the change on a 10-point scale ranging from a weak change (1) to very strong (10).

    Time frame: Weeks 12, 24

07

Results

Posted Jul 30, 2018

Participant flow

Adolescents or adults who have refractory epilepsy (drug resistant epilepsy per Kwan 2010) with a history of cluster seizures, also known as multiple episodes of acute repetitive seizures, for which acute treatment with a benzodiazepine was indicated as part of the standard of care or an individualized rescue treatment plan.

Participant flow — Overall Study
MilestoneDZNS - Adolescents (Ages 12 - 15)DZNS - Adults (Ages 16 - 65)
Started999
Completed013
Not completed986
Withdrew: Adverse event03
Withdrew: Lost to follow-up02
Withdrew: Physician decision01
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject29
Withdrew: Noncompliance with study drug03
Withdrew: Withdrawn due to termination by sponsor767

Outcome measures

PrimaryOlfactory Changes as Measured by the Smell Identification Test (SIT)

The SIT is a 50-item multiple-choice standardized test of olfactory function. Scoring of the test in the ability to smell ranges from normal (Normosmia: score 35 - 40 Women; 34 - 40 Men); to inability to smell (Anosmia score 6 - 18); or Malingering (not engaged in the test) ranges 0 - 5.

Time frame:
Screening, weeks 12, 24, 36, 48 and 51
Reported as:
Count of participants · Participants
Olfactory Changes as Measured by the Smell Identification Test (SIT)
ParticipantsDiazepam Nasal Spray (Adults)Diazepam Nasal Spray (Adolescents)
Screening — Normosmia180
Screening — Mild Microsmia151
Screening — Moderate Microsmia83
Screening — Severe Micromisia71
Screening — Anosmia90
Screening — Probable Malingering00
Week 12 — Normosmia60
Week 12 — Mild Microsmia160
Week 12 — Moderate Microsmia91
Week 12 — Severe Micromisia12
Week 12 — Anosmia20
Week 12 — Probable Malingering00
Week 24 — Normosmia50
Week 24 — Mild Microsmia90
Week 24 — Moderate Microsmia20
Week 24 — Severe Micromisia50
Week 24 — Anosmia00
Week 24 — Probable Malingering00
Week 36 — Normosmia20
Week 36 — Mild Microsmia60
Week 36 — Moderate Microsmia40
Week 36 — Severe Micromisia10
Week 36 — Anosmia10
Week 36 — Probable Malingering00
Week 48 — Normosmia00
Week 48 — Mild Microsmia50
Week 48 — Moderate Microsmia10
Week 48 — Severe Micromisia30
Week 48 — Anosmia10
Week 48 — Probable Malingering00
Week 51 — Normosmia10
Week 51 — Mild Microsmia30
Week 51 — Moderate Microsmia10
Week 51 — Severe Micromisia40
Week 51 — Anosmia10
Week 51 — Probable Malingering00
PrimaryChange From Baseline (Screening) in Nasal Mucosa.

Change from baseline treatment visits using a focused nasal exam was based on a scale of nasal irritation "none" to Grade 4 "septal perforation."

Time frame:
Screening, Weeks 12, 24, 36, 48 and 51
Reported as:
Count of participants · Participants
Change From Baseline (Screening) in Nasal Mucosa.
ParticipantsAdultsAdolescents
Screening : Nasal Irritation None676
Screening : Nasal Irritation Grade 1a101
Screening : Nasal Irritation Grade 1b30
Screening : Nasal Irritation Grade 200
Screening : Mucosal Edema None716
Screening : Mucosal Edema Mild91
Screening : Nasal Discharge None666
Screening : Nasal Discharge Mild141
Screening : Mucosal Erythema None655
Screening : Mucosal Erythema Mild132
Screening : Mucosal Erythema Moderate20
Screening : Mucosal Bleeding/Epistaxis None796
Screening : Mucosal Bleeding/Epistaxis Mild11
Screening : Crusting of Mucosa None777
Screening : Crusting of Mucosa Mild30
Week 12 : Nasal Irritation None504
Week 12 : Nasal Irritation Grade 1a50
Week 12 : Nasal Irritation Grade 1b30
Week 12 : Nasal Irritation Grade 210
Week 12 : Mucosal Edema None553
Week 12 : Mucosal Edema Mild41
Week 12 : Nasal Discharge None494
Week 12 : Nasal Discharge Mild100
Week 12 : Mucosal Erythema None394
Week 12 : Mucosal Erythema Mild200
Week 12 : Mucosal Erythema Moderate00
Week 12 : Mucosal Bleeding/Epistaxis None584
Week 12 : Mucosal Bleeding/Epistaxis Mild10
Week 12 : Crusting of Mucosa None584
Week 12 : Crusting of Mucosa Mild10
Week 24: Nasal Irritation None371
Week 24: Nasal Irritation Grade 1a10
Week 24: Nasal Irritation Grade 1b10
Week 24: Mucosal Edema None350
Week 24: Mucosal Edema Mild41
Week 24: Nasal Discharge None311
Week 24: Nasal Discharge Mild80
Week 24: Mucosal Erythema None331
Week 24: Mucosal Erythema Mild60
Week 24: Mucosal Bleeding/Epistaxis None391
Week 24: Crusting of Mucosa None371
Week 24: Crusting of Mucosa Mild20
Week 36: Nasal Irritation None211
Week 36: Nasal Irritation Grade 1a10
Week 36: Mucosal Edema None210
Week 36: Mucosal Edema Mild11
Week 36: Nasal Discharge None201
Week 36: Nasal Discharge Mild10
Week 36: Mucosal Erythema None201
Week 36: Mucosal Erythema Mild20
Week 36: Mucosal Bleeding/Epistaxis None221
Week 36: Crusting of Mucosa None211
Week 36: Crusting of Mucosa Mild10
Week 48: Nasal Irritation None120
Week 48: Nasal Irritation Grade 1a10
Week 48: Mucosal Edema None130
Week 48: Nasal Discharge None130
Week 48: Mucosal Erythema None130
Week 48: Mucosal Bleeding/Epistaxis None130
Week 48: Crusting of Mucosa None130
Week 51: Nasal Irritation None130
Week 51: Mucosal Edema None130
Week 51: Nasal Discharge None120
Week 51: Nasal Discharge Mild10
Week 51: Mucosal Erythema None130
Week 51: Mucosal Bleeding/Epistaxis None130
Week 51: Crusting of Mucosa None130
PrimaryChange in Taste as Measured by a Taste Change Questionnaire

Change in taste questionnaire was administered to subjects at every study visit only if the subject complained of a change in taste or as needed to report a related AE. The taste change profile included sweet, salty, sour, bitter, oily, sharp, chalky, metallic. The subject rated the change on a 10-point scale ranging from a weak change (1) to very strong (10).

Time frame:
Weeks 12, 24
Reported as:
Mean · units on a scale
Change in Taste as Measured by a Taste Change Questionnaire
units on a scaleDiazepam Nasal Spray (Adults)
Week 127.7 ± 2.73
Week 248.3 ± 0.50

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adults0/84 (0%)11/84 (13.1%)64/84 (76.2%)
Adolescents0/7 (0%)1/7 (14.3%)5/7 (71.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventAdultsAdolescents
Status EpilepticusNervous system disorders3/841/7
MigraineNervous system disorders2/840/7
LeukopeniaBlood and lymphatic system disorders1/840/7
Oesophagitis UlcerativeGastrointestinal disorders1/840/7
VomitingGastrointestinal disorders1/840/7
Otitis MediaInfections and infestations1/840/7
Septic ShockInfections and infestations1/840/7
DehydrationMetabolism and nutrition disorders1/840/7
Diebetes MellitusMetabolism and nutrition disorders1/840/7
Diabetic KetoacidosisMetabolism and nutrition disorders1/840/7
Most frequent other events
Most frequent other events
EventAdultsAdolescents
Nasal DiscomfortRespiratory, thoracic and mediastinal disorders25/842/7
DysgeusiaRespiratory, thoracic and mediastinal disorders15/840/7
Nasal Mucosal DisorderRespiratory, thoracic and mediastinal disorders6/841/7
RhinorrhoeaRespiratory, thoracic and mediastinal disorders8/841/7
Lacrimation increasedEye disorders7/841/7
Throat IrritationRespiratory, thoracic and mediastinal disorders7/840/7
OverdoseInjury, poisoning and procedural complications6/840/7
SomnolenceNervous system disorders6/840/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Diazapam Nasal Spray (DZNS) AdultsDiazapam Nasal Spray (DZNS) AdolescentsTotal
<=18 years7916
Between 18 and 65 years91091
>=65 years101
Age, Continuous
Age, Continuous(years)Diazapam Nasal Spray (DZNS) AdultsDiazapam Nasal Spray (DZNS) AdolescentsTotal
Mean34.6 ± 12.5813.4 ± 1.1332.9 ± 13.40
Sex: Female, Male
Sex: Female, Male(Participants)Diazapam Nasal Spray (DZNS) AdultsDiazapam Nasal Spray (DZNS) AdolescentsTotal
Female48351
Male51657
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diazapam Nasal Spray (DZNS) AdultsDiazapam Nasal Spray (DZNS) AdolescentsTotal
Hispanic or Latino628
Not Hispanic or Latino937100
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Diazapam Nasal Spray (DZNS) AdultsDiazapam Nasal Spray (DZNS) AdolescentsTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander505
Black or African American9110
White75883
More than one race202
Unknown or Not Reported707
Region of Enrollment
Region of Enrollment(Participants)Diazapam Nasal Spray (DZNS) AdultsDiazapam Nasal Spray (DZNS) AdolescentsTotal
United States999108
08

Study locations

33 sites
  • Acorda Site #227
    Phoenix, Arizona 85054, United States
  • Acorda Site #204
    Little Rock, Arkansas 72205, United States
  • Acorda Site #213
    Los Angeles, California 90095, United States
  • Acorda Site #220
    Orange, California 92868, United States
  • Acorda Site #206
    Orlando, Florida 32819, United States
  • Acorda Site #241
    Port Charlotte, Florida 33592, United States
  • Acorda Site #231
    Tallahassee, Florida 32308, United States
  • Acorda Site #201
    Tampa, Florida 33606, United States
  • Acorda Site #234
    Tampa, Florida 33609, United States
  • Acorda Site #217
    Augusta, Georgia 30912, United States
  • Acorda Site #232
    Honolulu, Hawaii 96817, United States
  • Acorda Site #225
    Fort Wayne, Indiana 46804, United States
  • Acorda Site #226
    Ames, Iowa 50010, United States
  • Acorda Site #202
    Bethesda, Maryland 20817, United States
  • Acorda Site #212
    Boston, Massachusetts 02115, United States
  • Acorda Site #214
    Boston, Massachusetts 02115, United States
  • Acorda Site #208
    Boston, Massachusetts 02215, United States
  • Acorda Site #216
    Kansas City, Missouri 64111, United States
  • Acorda Site #205
    Saint Louis, Missouri 63131, United States
  • Acorda Site #222
    Hackensack, New Jersey 07601, United States
  • Acorda Site #223
    New York, New York 10016, United States
  • Acorda Site #233
    Rochester, New York 14642, United States
  • Acorda Site #230
    Portland, Oregon 97239, United States
  • Acorda Site #219
    Philadelphia, Pennsylvania 19104, United States
  • Acorda Site #237
    Philadelphia, Pennsylvania 19107, United States
  • Acorda Site #203
    Charleston, South Carolina 29425, United States
  • Acorda Site #235
    Memphis, Tennessee 38103, United States
  • Acorda Site #218
    Nashville, Tennessee 37232, United States
  • Acorda Site #221
    Dallas, Texas 75251, United States
  • Acorda Site #229
    Houston, Texas 77030, United States
  • Acorda Site #215
    Richmond, Virginia 23298, United States
  • Acorda Site #224
    Renton, Washington 98057, United States
  • Acorda Site #210
    Madison, Wisconsin 53792, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Jul 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2014
First posted
Dec 15, 2014
Start
Dec 2014
Primary completionActual
Jul 2016
CompletionActual
Sep 2016
Results first posted
Jul 30, 2018
Last update
Jul 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02316847
Responsible party
Sponsor
First posted
Dec 15, 2014
Start date
Dec 2014
Primary completion
Jul 2016
Completion
Sep 2016
Results posted
Jul 30, 2018
Last update
Jul 30, 2018

Study contacts

MinJae Lee
study director · SK Biopharmaceuticals Co, Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion